Comparative Pharmacology
Head-to-head clinical analysis: ADMELOG SOLOSTAR versus MERILOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADMELOG SOLOSTAR versus MERILOG.
ADMELOG SOLOSTAR vs MERILOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro, a rapid-acting insulin analog, lowers blood glucose by binding to and activating the insulin receptor, leading to increased glucose uptake in peripheral tissues (e.g., skeletal muscle, fat) and suppression of hepatic glucose production.
Merilog is a recombinant human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis, and enhances protein synthesis.
Subcutaneous injection starting dose 0.2-0.4 units/kg/day divided into 1-2 injections, or 0.1-0.2 units/kg/meal for prandial coverage; typical total daily dose 0.5-1.0 units/kg.
10 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life: 5-6 hours for insulin lispro; clinical context: reflects duration of glucose-lowering effect, allowing dosing before meals.
The terminal elimination half-life is approximately 18 hours, allowing for once-daily dosing in most patients. In renal impairment (CrCl <30 mL/min), half-life is prolonged to >40 hours, requiring dose adjustment.
Renal: 30-80% of dose excreted unchanged in urine; biliary/fecal: negligible.
MERILOG is primarily excreted renally as unchanged drug (85%) and as minor metabolites (10%). Fecal excretion accounts for less than 5%.
Category C
Category C
Insulin
Insulin